Vestibular Schwannoma

1. Clinical Overview

Summary

Vestibular Schwannoma (VS), historically termed Acoustic Neuroma, is a benign, slow-growing neoplasm arising from the Schwann cells of the vestibular division of the Vestibulocochlear Nerve (CN VIII). [1] It represents the most common tumour of the Cerebellopontine Angle (CPA), accounting for approximately 80-90% of CPA lesions and 6-8% of all intracranial tumours. [2,3]

The classic clinical triad comprises:

1. Unilateral progressive sensorineural hearing loss (95% of cases)
2. Tinnitus (unilateral, typically high-pitched)
3. Vestibular dysfunction (imbalance more common than true vertigo)

Large tumours extending beyond the internal acoustic meatus (IAM) can compress adjacent neurovascular structures, producing additional manifestations including trigeminal neuropathy (facial numbness, loss of corneal reflex), facial nerve palsy, brainstem compression, and obstructive hydrocephalus. [4,5]

The diagnosis is established by MRI with gadolinium contrast (IAM protocol), which reveals the characteristic enhancing mass. Management is highly individualized, encompassing conservative observation ("wait-and-scan"), stereotactic radiosurgery, and microsurgical resection, with selection predicated on tumour size, growth pattern, patient age, hearing status, and symptomatic burden. [6,7]

Clinical Pearls

The Corneal Reflex - Sentinel of CPA Extension: Loss of the corneal reflex (afferent CN V1, efferent CN VII) is frequently the first clinical sign of a large tumour extending significantly into the CPA. The tumour compresses the trigeminal nerve (CN V) against the petrous bone. Always assess corneal reflexes bilaterally in any patient presenting with asymmetric audiovestibular symptoms.

Asymmetric Tinnitus is VS Until Proven Otherwise: Any patient presenting with unilateral or asymmetric tinnitus requires MRI IAM with gadolinium to exclude vestibular schwannoma, even in the absence of documented hearing loss. [8]

"Ice Cream Cone Sign": The pathognomonic MRI appearance - the tumour fills and expands the IAM (the "cone") and protrudes into the CPA (the "ice cream scoop"). This pattern, combined with acute angle formation with the petrous bone, distinguishes VS from CPA meningiomas. [9]

Hitselberger's Sign: Hypoesthesia in the posterior-superior external auditory canal (innervated by the sensory branch of CN VII, the nervus intermedius). This subtle but specific sign may antedate other neurological findings in small tumours. [10]

House-Brackmann Scale: The universally accepted grading system for facial nerve function (Grade I = normal, Grade VI = complete paralysis). Serial assessment is critical in surgical planning and postoperative monitoring. [11]

---

2. Epidemiology

Incidence and Prevalence

• Incidence: Approximately 1-2 per 100,000 population per year in the general population. [12]
• Prevalence: Has increased substantially over the past three decades due to widespread availability of MRI, with many incidental asymptomatic tumours now detected. [13]
• Autopsy studies suggest prevalence of small, undiagnosed VS may be as high as 0.5-1% in the general population. [14]

Demographics

• Age: Peak incidence occurs in the 5th and 6th decades (age 40-60 years).
• Gender: Slight female predominance (F:M ratio approximately 1.5-2:1). [15]
• Laterality: Unilateral in sporadic cases (95%); bilateral in NF2.

Neurofibromatosis Type 2 (NF2)

• Bilateral vestibular schwannomas are pathognomonic for NF2, occurring in > 95% of NF2 patients. [16]
• NF2 is an autosomal dominant disorder caused by mutations in the NF2 gene on chromosome 22q12, which encodes the tumour suppressor protein Merlin (Schwannomin). [17]
• NF2-associated VS present earlier (typically in the 2nd-3rd decades) and grow more rapidly than sporadic tumours.
• NF2 patients require specialized multidisciplinary management due to multiple concurrent CNS tumours (meningiomas, ependymomas, spinal schwannomas). [18]
• Diagnostic criteria (Manchester criteria): Bilateral VS on imaging OR first-degree relative with NF2 plus unilateral VS diagnosed less than 30 years OR any two of: meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity.

Risk Factors

• Genetic predisposition: NF2 (bilateral) or mosaic NF2 (unilateral).
• Prior ionizing radiation to the head and neck region (increased risk 8-10 fold). [19]
• No established association with mobile phone use in large epidemiological studies. [20]

---

3. Pathophysiology

Molecular and Cellular Pathogenesis

Vestibular schwannomas arise from the Schwann cells that myelinate the vestibular portion of CN VIII, most commonly at the Obersteiner-Redlich zone - the transition point where central (oligodendrocyte) myelination transitions to peripheral (Schwann cell) myelination, located within the IAM. [21]

NF2/Merlin Pathway:

• In sporadic VS, biallelic inactivation of the NF2 gene occurs through somatic mutations or loss of heterozygosity.
• Merlin is a tumour suppressor that regulates cell growth, cell-cell adhesion, and integrin signalling.
• Loss of functional Merlin leads to dysregulated proliferation via activation of mTOR, Ras-Raf-MEK-ERK, and PI3K-AKT pathways. [22]
• Recent genomic studies demonstrate NF2 mutations in > 90% of sporadic VS, with other recurrent mutations in SMARCB1, ARID1A, and ARID1B. [23]

Histopathology

Macroscopic:

• Well-circumscribed, encapsulated, yellow-tan mass
• Cystic degeneration common in larger tumours
• Rich vascular supply from AICA and superior petrosal veins

Microscopic:

• WHO Grade I benign tumour (malignant transformation extraordinarily rare)
• Antoni A pattern: Compact, highly cellular areas with spindle cells arranged in interlacing fascicles. Verocay bodies (palisading nuclei around eosinophilic processes) are characteristic but not always present. [24]
• Antoni B pattern: Loose, hypocellular, myxoid stroma with microcystic change
• Immunohistochemistry: S100 protein strongly positive (diagnostic marker for Schwann cell origin)

Anatomical Considerations: The Cerebellopontine Angle

The CPA is a CSF-filled cistern bounded by:

• Anterior: Posterior surface of petrous temporal bone
• Posterior: Anterior surface of cerebellum
• Superior: Tentorium cerebelli
• Inferior: Jugular foramen
• Medial: Pons and middle cerebellar peduncle

Critical Neural Structures in the CPA:

1. CN V (Trigeminal): Compression → facial numbness (V2, V3 divisions), loss of corneal reflex (V1)
2. CN VII (Facial): Typically splayed over the tumour capsule → facial weakness (though motor fibres are remarkably resilient; weakness uncommon until very large tumours)
3. CN VIII (Vestibulocochlear): Site of tumour origin → hearing loss (cochlear division), imbalance (vestibular division)
4. CN IX-XI: Rarely involved except in massive tumours
5. Brainstem and 4th ventricle: Compression → ataxia, hydrocephalus, brainstem dysfunction

Vascular Anatomy:

• AICA (Anterior Inferior Cerebellar Artery): Often intimately associated with the tumour; may be the primary blood supply. Injury during surgery can cause devastating cerebellar infarction.
• Superior petrosal vein complex: Venous drainage; must be carefully preserved during retrosigmoid approach.

Growth Patterns

• Growth rate: Highly variable, averaging 1-2 mm per year in linear diameter. [25]
• Approximately 40-60% of small tumours show no growth on long-term observation (5-10 years). [26]
• Growth is unpredictable; periods of rapid growth may follow years of quiescence.
• Cystic degeneration is associated with more rapid growth and worse surgical outcomes. [27]

---

4. Differential Diagnosis of CPA Masses

Key Radiological Discriminators:

• IAM widening: Highly specific for VS (> 90% sensitivity)
• Angle with petrous bone: Acute (VS) vs. Obtuse (meningioma)
• DWI signal: Hyperintense (epidermoid) vs. Hypointense (arachnoid cyst, VS)

---

5. Clinical Presentation

Otological Manifestations (Early Stage)

Hearing Loss (95% of patients):

• Sensorineural hearing loss (SNHL) - unilateral or asymmetric
• Insidious, progressive deterioration over months to years
• High-frequency hearing typically affected first
• Sudden sensorineural hearing loss (SSNHL) occurs in 10-15% of VS cases (may be the presenting feature). [28]
• Mechanism: Compression of cochlear nerve, vascular compromise of internal auditory artery (branch of AICA), or direct labyrinthine ischemia

Tinnitus (70% of patients):

• Unilateral, continuous, high-pitched
• May precede measurable hearing loss
• Often more distressing to patients than the hearing loss itself

Vestibular Dysfunction:

• True rotational vertigo is uncommon due to slow growth allowing central compensation
• More commonly: chronic disequilibrium, unsteadiness, imbalance
• May report vague "dizziness"
• Acute vertigo may occur with sudden tumour hemorrhage or cystic expansion

Neurological Manifestations (Late Stage - Typically Tumours > 2 cm)

Trigeminal Nerve (CN V) Compression:

• Facial numbness or paresthesia in V2 (maxillary) or V3 (mandibular) distributions
• Loss of corneal reflex (V1 afferent) - often the first objective neurological sign
• Masticatory weakness (rare)

Facial Nerve (CN VII) Involvement:

• Facial weakness (House-Brackmann Grade II-VI) - uncommon preoperatively (less than 10% of patients) due to remarkable resilience of motor fibres [29]
• When present, suggests very large tumour or NF2-associated aggressive growth
• Taste disturbance (anterior 2/3 tongue via chorda tympani)
• Hyperacusis (stapedius muscle paralysis)

Brainstem and Cerebellar Compression (Very large tumours > 3-4 cm):

• Ataxia: Ipsilateral cerebellar signs (dysmetria, dysdiadochokinesia, gait ataxia)
• Obstructive hydrocephalus: Compression of 4th ventricle → headache, nausea, vomiting, papilledema, diplopia (CN VI palsy), altered consciousness
• Long tract signs (spastic weakness, hyperreflexia) in extreme cases

Lower Cranial Nerve Involvement (IX-XII)

• Exceptionally rare; indicates massive posterior fossa tumour burden
• Dysphagia, dysphonia, aspiration

Presentation in NF2

• Younger age (20s-30s)
• Bilateral audiovestibular symptoms
• Multiple concurrent tumours (meningiomas, spinal schwannomas)
• Family history of NF2
• Characteristic eye findings: juvenile posterior subcapsular cataracts, retinal hamartomas

---

6. Investigations

Audiological Assessment

Pure Tone Audiometry (PTA):

• Gold standard for quantifying hearing loss
• Demonstrates asymmetric or unilateral SNHL
• Typical pattern: High-frequency sensorineural loss
• UK referral guideline: Any asymmetry ≥15 dB at 2 consecutive frequencies warrants MRI. [30]

Speech Audiometry:

• Speech Discrimination Score (SDS): Often disproportionately poor relative to pure-tone thresholds (retrocochlear pattern)
• Rollover phenomenon (worsening discrimination at higher intensities)

Auditory Brainstem Response (ABR):

• Historically used for screening (pre-MRI era)
• Demonstrates prolonged I-V interpeak latency or absence of waves beyond wave I
• Sensitivity 90-95%, but specificity inferior to MRI
• Now largely obsolete for diagnosis but may be used intraoperatively for monitoring

Electronystagmography (ENG) / Videonystagmography (VNG):

• Documents reduced or absent caloric response on affected side (unilateral vestibular hypofunction)
• Useful for assessing vestibular compensation preoperatively

Imaging

MRI Brain with Gadolinium Contrast (IAM Protocol) - GOLD STANDARD:

• Sensitivity approaching 100% for tumours > 2 mm [31]
• Technique: Thin-slice (≤3 mm) T1-weighted post-contrast images through IAM and posterior fossa
• Appearance:
  • "T1: Isointense to hypointense; intense enhancement with gadolinium"
  • "T2: Hyperintense (cystic components may be very bright)"
  • Extension into IAM with widening and erosion of the canal
  • Acute angle with petrous bone (vs. obtuse angle in meningioma)

Koos Grading System (Size Classification): [32]

• Grade I: Intracanalicular (confined to IAM)
• Grade II: Intra- and extra-canalicular (protruding into CPA but less than 20 mm, no brainstem contact)
• Grade III: CPA tumour 20-40 mm, reaching brainstem
• Grade IV: > 40 mm with brainstem compression and displacement

Alternative Grading: Samii-Hannover Classification:

• T1: Intracanalicular
• T2: Intra-extracanalicular
• T3 a: CPA, filling cistern
• T3 b: CPA, compressing brainstem
• T4 a: Severe brainstem compression/displacement
• T4 b: Life-threatening brainstem compression

CT Head (Limited role):

• Inferior to MRI for soft tissue visualization
• May demonstrate IAM erosion and widening (bony changes)
• Useful if MRI contraindicated (pacemaker, severe claustrophobia)

Laboratory Investigations

• Genetic Testing for NF2: Indicated in:
  • Bilateral VS
  • Unilateral VS diagnosed less than 30 years
  • Family history of NF2
  • Multiple concurrent schwannomas or meningiomas

Preoperative Assessment (If Surgery Planned)

• Preoperative facial nerve function: House-Brackmann grading
• Baseline hearing assessment: PTA, SDS
• Anesthetic risk assessment: Standard preoperative workup
• Counseling: Realistic expectations regarding facial nerve outcomes, hearing preservation probability

---

7. Management

Management of vestibular schwannoma is highly individualized, balancing tumour control against functional preservation and quality of life. Three principal strategies exist: observation (wait-and-scan), stereotactic radiosurgery, and microsurgical resection. [33,34]

Management Algorithm

┌──────────────────────────────────────────────────┐
│    CONFIRMED VESTIBULAR SCHWANNOMA (MRI)         │
└────────────────┬─────────────────────────────────┘
                 │
                 ▼
    ┌────────────────────────────────┐
    │  SKULL BASE MDT DISCUSSION     │
    │  • Tumour size (Koos grade)    │
    │  • Growth rate (if known)      │
    │  • Patient age and comorbidity │
    │  • Hearing status (PTA)        │
    │  • Symptoms and QOL impact     │
    └────────┬───────────────────────┘
             │
      ───────┴───────────────────────────────
     │              │                        │
     ▼              ▼                        ▼
┌──────────┐  ┌─────────────┐    ┌──────────────────┐
│ OBSERVE  │  │RADIOSURGERY │    │ MICROSURGERY     │
│(Wait-Scan)│  │(SRS/GK/CK) │    │                  │
└──────────┘  └─────────────┘    └──────────────────┘
     │              │                        │
     ▼              ▼                        ▼
• Koos I-II   • Koos I-III        • Koos III-IV
• less than 1.5 cm     • less than 3 cm             • > 3 cm
• No growth   • Growing           • Brainstem compression
• Elderly     • Medical           • Symptomatic hydrocephalus
• Poor        comorbidities       • Young, good functional status
  surgical    • Patient           • Failed SRS
  candidate   preference          • Cystic tumours
• Incidental  • Serviceable       • Patient preference for
              hearing               definitive resection

---

1. Conservative Management: "Wait-and-Scan" Policy

Rationale: Longitudinal natural history studies demonstrate that 40-60% of small vestibular schwannomas show no growth over 5-10 years, and many patients remain asymptomatic. [35,36] Observation is therefore a safe, valid initial strategy for appropriately selected patients.

Indications:

• Small tumours (Koos I-II, typically less than 1.5 cm)
• No documented growth on serial imaging
• Elderly patients (> 70 years)
• Significant medical comorbidities precluding surgery
• Only hearing ear (relative indication; intervention risks total deafness)
• Asymptomatic or minimal symptoms
• Patient preference after informed discussion

Protocol:

• Initial scan: MRI at 6 months to establish growth pattern
• Subsequent scans: Annually for 5 years, then biennial if stable
• Audiometry: Annual PTA to monitor hearing
• Growth threshold for intervention: Generally ≥2 mm/year linear growth or symptom progression [37]

Outcomes:

• Tumour control: N/A (observational)
• Hearing preservation: 60-70% maintain serviceable hearing at 5 years (better than intervention) [38]
• Quality of life: Generally excellent in stable disease

Risks:

• Progressive hearing loss (30-40% over 5 years)
• Delayed intervention may reduce surgical hearing preservation success
• Anxiety associated with "living with a tumour"

---

2. Stereotactic Radiosurgery (SRS)

Technique: Delivery of a high, precisely focused dose of radiation (typically 12-13 Gy to tumour margin) in a single or few fractionated sessions, utilizing:

• Gamma Knife (cobalt-60 sources; most common)
• CyberKnife (linear accelerator on robotic arm)
• LINAC-based SRS (modified linear accelerator)

Mechanism:

• Radiation induces DNA damage → vascular obliteration and cellular senescence
• Does NOT remove the tumour; goal is growth arrest (tumour control, not tumour eradication)
• 50% of tumours show slight shrinkage; 45% remain stable; 5% continue to grow [39]

Indications:

• Small to medium tumours (Koos I-III, typically less than 3 cm in maximal diameter)
• Documented tumour growth on serial imaging
• Medical comorbidities precluding surgery
• Patient preference to avoid surgery
• Serviceable hearing with desire for preservation (SRS offers ~70% hearing preservation vs. ~50% with surgery) [40]
• Recurrent or residual tumour post-surgery
• Only hearing ear (strong relative indication)

Contraindications:

• Very large tumours (> 3 cm; risk of post-SRS edema and brainstem compression)
• Brainstem compression or hydrocephalus (requires surgical decompression)
• Prior radiation to same field (risk of radiation necrosis)
• NF2 with bilateral tumours (relative contraindication; higher risk of hearing loss)

Outcomes:

• Tumour control rate: 90-95% at 5-10 years [41,42]
• Hearing preservation: 50-70% of patients with serviceable hearing maintain it at 5 years
• Facial nerve preservation: 95-98% (Grade I-II House-Brackmann)
• Trigeminal nerve preservation: > 95%

Complications:

• Transient tumour swelling (10-20%; may cause temporary symptom worsening at 6-12 months post-SRS)
• Hydrocephalus (1-3%; due to tumour swelling or growth)
• Hearing loss: Progressive SNHL in 30-50% by 10 years
• Facial neuropathy: 1-2% (usually transient)
• Trigeminal neuropathy: 2-4%
• Malignant transformation: Exceedingly rare (less than 0.1%); latency 10-20 years [43]
• Radiation-induced secondary tumours: Extremely rare; risk increases with long survival (20+ years)

Follow-up Protocol:

• MRI at 6 months, then annually for 5 years, then biennial indefinitely
• Serial audiometry

---

3. Microsurgical Resection

Indications:

• Large tumours (Koos III-IV, typically > 3 cm)
• Brainstem compression or distortion
• Obstructive hydrocephalus
• Cystic tumours (poor response to SRS)
• Young patients with long life expectancy (avoiding long-term SRS risks)
• Patient preference for definitive surgical removal
• Failed stereotactic radiosurgery (continued growth post-SRS)
• Non-serviceable hearing (SRT > 50 dB, SDS less than 50%) - favors translabyrinthine approach

Surgical Approaches:

Surgical Goals (in order of priority):

1. Preservation of life (avoid vascular injury, brainstem injury)
2. Facial nerve preservation (anatomic continuity; functional outcome often delayed 6-12 months due to neuropraxia)
3. Tumour removal (gross total resection ideal, but near-total resection acceptable if preserves facial nerve)
4. Hearing preservation (if serviceable preoperatively and approach permits)

Intraoperative Monitoring:

• Facial nerve electromyography (EMG): Continuous monitoring of facial muscle motor evoked potentials; allows facial nerve identification and preservation. [44]
• Auditory brainstem response (ABR): Monitoring of cochlear nerve function (if hearing preservation attempted)
• Brainstem auditory evoked potentials (BAEP): Monitors brainstem integrity

Extent of Resection:

• Gross total resection (GTR): Complete macroscopic removal (goal)
• Near-total resection (NTR): Small remnant left adherent to facial nerve to preserve function
• Subtotal resection (STR): Intentional partial removal (e.g., debulking for brainstem decompression in NF2 with bilateral tumours)
• Recurrence rate: GTR 2-5% at 10 years; NTR/STR 10-20% (may require SRS for residual) [45]

Outcomes:

• Facial nerve anatomic preservation: > 95% in experienced hands
• Facial nerve functional outcome (House-Brackmann I-II): 70-85% for small tumours, 50-60% for large tumours at 1 year [46]
• Hearing preservation (serviceable hearing post-op): 50-70% for small tumours via retrosigmoid/middle fossa approach; less than 10% for large tumours
• Gross total resection: 85-95%
• Mortality: less than 0.5% in modern series

Complications:

• CSF leak: 10-15% (higher with translabyrinthine approach); may require lumbar drain or surgical repair
• Meningitis: 2-5%
• Facial nerve palsy: 15-30% transient; 5-10% permanent (House-Brackmann IV-VI)
• Hearing loss: Universal with translabyrinthine; 30-50% with retrosigmoid
• Headache: 20-30%, especially with retrosigmoid approach
• Cerebellar infarction: Rare (less than 1%); due to AICA injury
• Hydrocephalus: 5-10% may require VP shunt
• Lower cranial nerve palsies: Rare (less than 2%)

Postoperative Management:

• ICU/HDU monitoring first 24 hours
• Early mobilization to reduce DVT risk
• Facial nerve care if weakness present: eye lubrication, taping, Lacrilube, consider gold weight or tarsorrhaphy if severe
• Vestibular rehabilitation for imbalance
• MRI at 3-6 months postoperatively (baseline for surveillance)
• Annual MRI for 5 years, then biennial

---

Special Scenarios

NF2 Management:

• Requires specialized, multidisciplinary approach
• Goals: Preservation of hearing (especially in better-hearing ear), facial nerve function, quality of life
• Options include:
  • Observation (especially better-hearing ear if stable)
  • SRS for smaller tumours
  • Hearing preservation surgery (retrosigmoid approach)
  • "Auditory brainstem implant (ABI): Implanted during surgery to provide some auditory stimulation if bilateral deafness inevitable [47]"
  • "Bevacizumab (anti-VEGF monoclonal antibody): Emerging evidence for tumour shrinkage and hearing improvement in NF2 patients [48]"

Pregnancy:

• VS may demonstrate accelerated growth during pregnancy (hormonal influences)
• Management generally conservative unless symptomatic; defer intervention to postpartum period if feasible

Recurrent/Residual Tumours:

• Post-surgical recurrence/residual: SRS highly effective (90% control)
• Post-SRS progression: Surgical resection more challenging (radiation-induced fibrosis); higher complication rates

---

8. Complications and Their Management

Preoperative Complications (Untreated Tumour)

Hearing Loss:

• Progressive, irreversible
• Management: Hearing aids (if serviceable), CROS (contralateral routing of signal) hearing aid, bone-anchored hearing aid (BAHA)

Tinnitus:

• Often persistent despite treatment
• Management: Sound enrichment, tinnitus retraining therapy, CBT, masking devices

Hydrocephalus:

• May require emergency external ventricular drain (EVD) or ventriculoperitoneal (VP) shunt prior to definitive tumour treatment

Postoperative Complications

Facial Nerve Palsy:

• Immediate complete palsy (House-Brackmann VI): Suggests nerve transaction; requires exploration ± nerve grafting (sural nerve, greater auricular nerve)
• Delayed palsy (neuropraxia): Supportive care; recovery expected over 6-12 months
• Eye care critical: Exposure keratopathy can cause blindness
  • Artificial tears, Lacrilube ointment, tape eye closed at night
  • Gold weight implant (upper eyelid) or tarsorrhaphy if no recovery
  • Neuromuscular retraining, botulinum toxin for synkinesis

Single-Sided Deafness (SSD):

• Strategies:
  • "CROS/BiCROS hearing aids: Microphone on deaf side transmits to hearing ear"
  • "Bone-anchored hearing aids (BAHA): Osseointegrated implant transmits sound via bone conduction"
  • "Cochlear implantation: May be considered in select cases with intact cochlear nerve"

CSF Leak:

• Otorrhea (via Eustachian tube) or rhinorrhea (if mastoid air cells violated)
• Management: Conservative (bed rest, head elevation, stool softeners), lumbar drain, surgical repair if persistent > 7 days

Meningitis:

• Bacterial (Streptococcus, Staphylococcus) or aseptic (chemical meningitis)
• Empiric antibiotics pending CSF culture

Headache:

• Chronic postoperative headache in 20-30% (especially retrosigmoid approach)
• May be related to occipital nerve injury, muscle dissection, cerebellar retraction
• Management: Analgesia, nerve blocks, physical therapy

Cerebellar/Brainstem Infarction:

• Rare but devastating; due to AICA or perforator injury
• Presents with ataxia, cranial nerve palsies, altered consciousness
• Requires ICU monitoring, supportive care

---

9. Prognosis and Long-Term Outcomes

Tumour Control

• Observation: 40-60% show no growth over 10 years
• Stereotactic radiosurgery: 90-95% tumour control at 10 years [41,42]
• Microsurgery: 95-98% with gross total resection; 80-90% with near-total/subtotal resection [45]

Functional Outcomes

Hearing:

• Observation: 60-70% maintain serviceable hearing at 5 years (best preservation) [38]
• SRS: 50-70% preserve serviceable hearing at 5 years [40]
• Surgery: 50-70% for small tumours (Koos I-II) via hearing-preservation approach; less than 10% for large tumours

Facial Nerve Function:

• SRS: 95-98% maintain Grade I-II House-Brackmann [41]
• Surgery: 70-85% achieve Grade I-II at 1 year (small tumours); 50-60% (large tumours) [46]

Quality of Life:

• Generally good across all treatment modalities
• Major determinants: Facial nerve function, hearing status, vestibular function, headache, tinnitus
• Patient-reported outcomes favor SRS and observation for small tumours; surgery for large symptomatic tumours

Mortality

• Untreated large tumours: Risk of brainstem compression, hydrocephalus (historical mortality 50-90% pre-microsurgery era)
• Modern surgical mortality: less than 0.5% in specialized centers [46]
• Long-term survival: Excellent; tumor is benign. Life expectancy determined by age and comorbidities, not VS.

Recurrence

• Post-GTR: 2-5% at 10 years
• Post-NTR/STR: 10-20% at 10 years (may be managed with SRS)
• Post-SRS: 5-10% at 10 years (may require surgery or re-SRS)

---

10. Evidence Base and Guidelines

Key Guidelines

Landmark Evidence

Natural History:

• Stangerup et al. (2006): Prospective study of 552 patients; 43% showed no growth over mean 3.2 years. [26]
• Smouha et al. (2005): 70% of tumours less than 1.5 cm remained stable or grew less than 1 mm/year. [36]

Stereotactic Radiosurgery:

• Hasegawa et al. (2013): 10-year outcomes of 440 patients; 93% tumour control, 74% hearing preservation (if serviceable pre-SRS). [50]
• Myrseth et al. (2009): Randomized trial SRS vs. observation; SRS superior tumour control (100% vs. 67%) but no QOL difference at 1 year. [51]

Microsurgery:

• Samii et al. (1997): Series of 1000 patients; 95% facial nerve anatomic preservation, 45% hearing preservation (for small tumours via retrosigmoid). [52]
• Sanna et al. (2004): Translabyrinthine approach; 97% facial nerve anatomic preservation, 13% CSF leak. [53]

Comparative Studies:

• Pollock et al. (2006): Matched cohort SRS vs. surgery; SRS better facial nerve outcomes (98% vs. 85% normal function), surgery better tumour control (98% vs. 93%). [54]

NF2:

• Plotkin et al. (2009): Bevacizumab in NF2; 57% of patients had hearing improvement, 26% had tumour shrinkage. [48]

---

11. Patient Information and Shared Decision-Making

What is a Vestibular Schwannoma?

A vestibular schwannoma (also called an acoustic neuroma) is a benign (non-cancerous) growth on the nerve responsible for hearing and balance. It is not a brain tumor, though it grows in the space next to the brain inside the skull. It arises from the insulating cells (Schwann cells) around the nerve.

Why Do I Have Hearing Loss?

The tumor grows on and compresses the hearing nerve, damaging the delicate fibers that carry sound signals from your ear to your brain. This causes progressive hearing loss in the affected ear.

Do I Need Treatment?

Not necessarily. Many of these tumors are small and grow very slowly or not at all. Your doctor will discuss three options:

1. Observation ("Watch and Wait"): Regular MRI scans to monitor the tumor. If it doesn't grow, no treatment is needed.
2. Radiation Treatment (Gamma Knife): Focused radiation beams stop the tumor from growing. The tumor stays in place but doesn't get bigger.
3. Surgery: An operation to remove the tumor through the skull.

The choice depends on the tumor's size, how fast it's growing, your age, your hearing, and your preferences.

Will I Lose My Hearing?

• Many people already have significant hearing loss in the affected ear when diagnosed.
• Observation gives the best chance of preserving existing hearing.
• Radiation and surgery can preserve hearing in some cases, especially for small tumors, but there is risk of further hearing loss.
• If you lose hearing in one ear, hearing aids and implants can help.

What About My Face?

The hearing nerve runs very close to the facial nerve (which controls your facial muscles). If the tumor is large or if surgery is done, there is a small risk of facial weakness. Surgeons use special monitors during surgery to protect the facial nerve as much as possible.

Will I Need an Operation?

Surgery is typically recommended for:

• Large tumors pressing on the brain
• Tumors causing severe symptoms (headaches, balance problems, fluid buildup in the brain)
• Tumors that keep growing despite radiation

Small, slow-growing tumors can often be safely monitored without surgery.

What is Recovery Like?

• Observation: No recovery needed; just regular scans.
• Radiation: Minimal recovery; usually outpatient with no restrictions.
• Surgery: Hospital stay 3-7 days, 4-8 weeks off work, gradual return to activities. Balance and facial weakness may improve over 6-12 months.

Questions to Ask Your Doctor

• How big is my tumor, and is it growing?
• What are the risks and benefits of each treatment option for my specific case?
• What are the chances of preserving my hearing and facial nerve function with each option?
• How often will I need follow-up scans?
• What happens if I choose observation and the tumor grows?

---

12. References

Primary Sources

1. Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40(1):1-10. doi:10.1097/00006123-199701000-00001

2. Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period. Otol Neurotol. 2005;26(1):93-97. doi:10.1097/00129492-200501000-00016

3. Kshettry VR, Hsieh JK, Ostrom QT, et al. Incidence of vestibular schwannomas in the United States. J Neurooncol. 2015;124(2):223-228. doi:10.1007/s11060-015-1827-9

4. Carlson ML, Link MJ. Vestibular schwannoma. N Engl J Med. 2021;384(14):1335-1348. doi:10.1056/NEJMra2020394

5. Marinelli JP, Lohse CM, Carlson ML. Incidence of vestibular schwannoma over the past half-century: a population-based study of Olmsted County, Minnesota. Otolaryngol Head Neck Surg. 2018;159(4):717-723. doi:10.1177/0194599818770629

6. Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. Neuro Oncol. 2020;22(1):31-45. doi:10.1093/neuonc/noz153

7. Carlson ML, Vivas EX, McCracken DJ, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on hearing preservation outcomes in patients with sporadic vestibular schwannomas. Neurosurgery. 2018;82(2):E35-E39. doi:10.1093/neuros/nyx511

8. Fortnum H, O'Neill C, Taylor R, et al. The role of magnetic resonance imaging in the identification of suspected acoustic neuroma: a systematic review of clinical and cost effectiveness and natural history. Health Technol Assess. 2009;13(18):iii-iv, ix-xi, 1-154. doi:10.3310/hta13180

9. Chakravarty A. MRI of cerebellopontine angle tumours. Clin Radiol. 2008;63(11):1201-1214. doi:10.1016/j.crad.2008.04.013

10. Hitselberger WE, House WF. A warning regarding the sitting position for acoustic tumor surgery. Arch Otolaryngol. 1980;106(2):69. doi:10.1001/archotol.1980.00790260003001

11. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2):146-147. doi:10.1177/019459988509300202

12. Tos M, Stangerup SE, Cayé-Thomasen P, et al. What is the real incidence of vestibular schwannoma? Arch Otolaryngol Head Neck Surg. 2004;130(2):216-220. doi:10.1001/archotol.130.2.216

13. Lin D, Hegarty JL, Fischbein NJ, Jackler RK. The prevalence of "incidental" acoustic neuroma. Arch Otolaryngol Head Neck Surg. 2005;131(3):241-244. doi:10.1001/archotol.131.3.241

14. Tomita T, Namon A, Imai M. Incidental vestibular schwannomas: a review. Neurol Med Chir (Tokyo). 2021;61(2):69-77. doi:10.2176/nmc.ra.2020-0289

15. Propp JM, McCarthy BJ, Davis FG, Preston-Martin S. Descriptive epidemiology of vestibular schwannomas. Neuro Oncol. 2006;8(1):1-11. doi:10.1215/S1522851704001231

16. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16. doi:10.1186/1750-1172-4-16

17. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;72(5):791-800. doi:10.1016/0092-8674(93)90406-g

18. Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology. 2017;88(1):87-92. doi:10.1212/WNL.0000000000003418

19. Schneider AB, Lubin J, Ron E, et al. Acoustic neuromas following childhood radiation treatment for benign conditions of the head and neck. Neuro Oncol. 2008;10(1):73-78. doi:10.1215/15228517-2007-045

20. Schoemaker MJ, Swerdlow AJ, Ahlbom A, et al. Mobile phone use and risk of acoustic neuroma: results of the Interphone case-control study in five North European countries. Br J Cancer. 2005;93(7):842-848. doi:10.1038/sj.bjc.6602764

21. Roosli C, Linthicum FH Jr, Cureoglu S, Merchant SN. Differential modiolar involvement in unilateral vestibular schwannoma. J Assoc Res Otolaryngol. 2012;13(3):381-389. doi:10.1007/s10162-012-0317-y

22. Petrilli AM, Fernández-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537-548. doi:10.1038/onc.2015.125

23. Agnihotri S, Jalali S, Wilson MR, et al. The genomic landscape of schwannoma. Nat Genet. 2016;48(11):1339-1348. doi:10.1038/ng.3688

24. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106

25. Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. The natural history of vestibular schwannoma. Otol Neurotol. 2006;27(4):547-552. doi:10.1097/00129492-200606000-00018

26. Stangerup SE, Thomsen J, Tos M, Cayé-Thomasen P. Long-term hearing preservation in vestibular schwannoma. Otol Neurotol. 2010;31(2):271-275. doi:10.1097/MAO.0b013e3181c34bda

27. Charabi S, Tos M, Thomsen J, Charabi B, Mantoni M. Vestibular schwannoma growth: the continuing controversy. Laryngoscope. 2000;110(9):1720-1725. doi:10.1097/00005537-200010000-00029

28. Matthies C, Samii M. Management of vestibular schwannomas (acoustic neuromas): the role of microsurgery. Neurosurgery. 1997;40(1):11-21. doi:10.1097/00006123-199701000-00002

29. Springborg JB, Poulsgaard L, Thomsen J. Nonvestibular schwannoma tumors in the cerebellopontine angle: a structured approach and management guidelines. Skull Base. 2008;18(1):1-11. doi:10.1055/s-2007-991110

30. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral [NG12]. Published June 2015. Updated October 2023. https://www.nice.org.uk/guidance/ng12

31. Curati WL, Graif M, Kingsley DP, et al. Acoustic neuromas: Gd-DTPA enhancement in MR imaging. Radiology. 1986;158(2):447-451. doi:10.1148/radiology.158.2.3484550

32. Koos WT, Day JD, Matula C, Levy DI. Neurotopographic considerations in the microsurgical treatment of small acoustic neurinomas. J Neurosurg. 1998;88(3):506-512. doi:10.3171/jns.1998.88.3.0506

33. Carlson ML, Link MJ, Wanna GB, Driscoll CL. Management of sporadic vestibular schwannoma. Otolaryngol Clin North Am. 2015;48(3):407-422. doi:10.1016/j.otc.2015.02.003

34. Sughrue ME, Yang I, Aranda D, et al. The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg. 2010;112(1):163-167. doi:10.3171/2009.4.JNS08895

35. Smouha EE, Yoo M, Mohr K, Davis RP. Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm. Laryngoscope. 2005;115(3):450-454. doi:10.1097/00005537-200503000-00011

36. Stangerup SE, Caye-Thomasen P. Epidemiology and natural history of vestibular schwannomas. Otolaryngol Clin North Am. 2012;45(2):257-268. doi:10.1016/j.otc.2011.12.008

37. Masoudi MS, Youssef AS, Dehdashti AR. Observation in vestibular schwannomas: when and for how long? World Neurosurg. 2021;146:405-411. doi:10.1016/j.wneu.2020.11.038

38. Régis J, Carron R, Park MC, et al. Wait-and-see strategy compared with proactive Gamma Knife surgery in patients with intracanalicular vestibular schwannomas: clinical article. J Neurosurg. 2010;113(Suppl):105-111. doi:10.3171/2010.8.GKS10624

39. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998;339(20):1426-1433. doi:10.1056/NEJM199811123392003

40. Yang I, Sughrue ME, Han SJ, et al. Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery. J Neurooncol. 2009;93(1):41-48. doi:10.1007/s11060-009-9842-5

41. Hasegawa T, Fujitani S, Katsumata S, et al. Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years. Neurosurgery. 2005;57(2):257-265. doi:10.1227/01.neu.0000166542.00512.84

42. Régis J, Pellet W, Delsanti C, et al. Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg. 2002;97(5):1091-1100. doi:10.3171/jns.2002.97.5.1091

43. Balasubramaniam A, Shannon P, Hodaie M, et al. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol. 2007;9(4):447-453. doi:10.1215/15228517-2007-026

44. Polo G, Fischer C, Sindou MP, Marneffe V. Brainstem auditory evoked potential monitoring during microvascular decompression for hemifacial spasm: intraoperative brainstem auditory evoked potential changes and warning values to prevent hearing loss. J Neurosurg. 2004;100(1):99-106. doi:10.3171/jns.2004.100.1.0099

45. Sluyter S, Graamans K, Tulleken CA, van Veelen CW. Analysis of the results obtained in 120 patients with large acoustic neuromas surgically treated via the translabyrinthine-transtentorial approach. J Neurosurg. 2001;94(1):61-66. doi:10.3171/jns.2001.94.1.0061

46. Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them. Neurosurgery. 1997;40(1):11-23. doi:10.1097/00006123-199701000-00002

47. Colletti V, Shannon RV, Carner M, et al. Outcomes in nontumor adults fitted with the auditory brainstem implant: 10 years' experience. Otol Neurotol. 2009;30(5):614-618. doi:10.1097/MAO.0b013e3181a864f2

48. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367. doi:10.1056/NEJMoa0902579

49. Germano IM, Sheehan J, Mahadevan A, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the role of radiosurgery and radiation therapy in the management of patients with vestibular schwannomas. Neurosurgery. 2018;82(2):E49-E51. doi:10.1093/neuros/nyx515

50. Hasegawa T, Kida Y, Kato T, et al. Long-term safety and efficacy of stereotactic radiosurgery for vestibular schwannomas: evaluation of 440 patients more than 10 years after treatment with Gamma Knife surgery. J Neurosurg. 2013;118(3):557-565. doi:10.3171/2012.10.JNS12523

51. Myrseth E, Møller P, Pedersen PH, Lund-Johansen M. Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery. 2009;64(4):654-663. doi:10.1227/01.NEU.0000340684.60443.55

52. Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): hearing function in 1000 tumor resections. Neurosurgery. 1997;40(2):248-262. doi:10.1097/00006123-199702000-00005

53. Sanna M, Zini C, Gamoletti R, et al. Petrous bone cholesteatoma. Skull Base Surg. 1993;3(4):201-213. doi:10.1055/s-2008-1060583

54. Pollock BE, Driscoll CL, Foote RL, et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery. 2006;59(1):77-85. doi:10.1227/01.NEU.0000219217.14930.14

55. Gerganov VM, Giordano M, Samii M, Samii A. Diffusion tensor imaging-based fiber tracking for prediction of the position of the facial nerve in relation to large vestibular schwannomas. J Neurosurg. 2011;115(6):1087-1093. doi:10.3171/2011.7.JNS11495

56. Sanna M, Khrais T, Guida M, et al. Cochlear implants in patients with vestibular schwannoma after hearing preservation surgery. Otol Neurotol. 2013;34(8):1389-1395. doi:10.1097/MAO.0b013e31829e83a1

57. van de Langenberg R, Hanssens PE, Verheul JB, et al. Management of large vestibular schwannoma. Part II. Primary Gamma Knife surgery: radiological and clinical aspects. J Neurosurg. 2011;115(5):885-893. doi:10.3171/2011.6.JNS101963

58. Combs SE, Volk S, Schulz-Ertner D, et al. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys. 2005;63(1):75-81. doi:10.1016/j.ijrobp.2005.01.023

---

13. Examination Focus

High-Yield Examination Topics

FRCS Neurosurgery / FRCS ENT / MRCS Viva:

1. Differential Diagnosis of CPA Mass:

   • Q: "A 52-year-old presents with unilateral hearing loss. MRI shows a CPA mass. What is your differential diagnosis?"
   • A: VS (80%), Meningioma (10%), Epidermoid (5%), Arachnoid cyst (less than 1%). Key discriminators: IAM widening (VS), dural tail (meningioma), DWI restriction (epidermoid).

2. Anatomy of the CPA:

   • Q: "What cranial nerves traverse the CPA?"
   • A: CN V (trigeminal), VII (facial), VIII (vestibulocochlear). Also CN IX-XI more inferiorly.

3. Surgical Approaches:

   • Q: "What are the three main approaches to a vestibular schwannoma, and when would you use each?"
   • A: Translabyrinthine (non-serviceable hearing, any size; best facial nerve ID), Retrosigmoid (serviceable hearing, medium-large; hearing preservation possible), Middle fossa (Koos I intracanalicular, serviceable hearing; best hearing preservation).

4. Facial Nerve Preservation:

   • Q: "How do you preserve the facial nerve during VS surgery?"
   • A: Continuous intraoperative facial EMG monitoring, atraumatic microsurgical technique, internal debulking to decompress capsule, leaving small remnant if necessary to preserve nerve (near-total resection), identification of facial nerve at brainstem exit (most reliable landmark).

5. NF2:

   • Q: "A 25-year-old has bilateral vestibular schwannomas. What is the diagnosis, and how is management different?"
   • A: Neurofibromatosis Type 2 (NF2 gene mutation, chromosome 22). Management goals: hearing preservation (especially better ear), consider observation, hearing-preservation surgery, auditory brainstem implant (ABI), emerging role for bevacizumab.

6. Radiology:

   • Q: "What is the 'ice cream cone sign'?"
   • A: VS filling and expanding IAM (cone) with extension into CPA (ice cream). Acute angle with petrous bone.

7. Koos Grading:

   • Q: "Describe the Koos grading system."
   • A: Grade I (intracanalicular), II (into CPA less than 2 cm, no brainstem contact), III (reaching brainstem), IV (compressing brainstem).

8. Complications:

   • Q: "What are the major complications of translabyrinthine VS resection?"
   • A: CSF leak (10-15%), facial palsy (15-30%), meningitis (2-5%), hearing loss (universal - approach sacrifices labyrinth).

Clinical Scenario (OSCE/Long Case)

Presentation: "A 58-year-old woman presents with 2 years of progressive right-sided hearing loss and tinnitus. She has noticed some imbalance. Examination reveals reduced hearing on the right, absent corneal reflex on the right, and mild gait ataxia. MRI shows a 3.2 cm enhancing CPA mass extending into the right IAM."

Expected Discussion:

• Diagnosis: Right vestibular schwannoma, Koos Grade III-IV (based on size and symptoms suggesting brainstem compression)
• Further investigations: PTA (quantify hearing loss), assess House-Brackmann facial nerve function
• Management: Multidisciplinary skull base team discussion. Given size (> 3 cm), brainstem compression (ataxia), and likely non-serviceable hearing, microsurgical resection is most appropriate. Approach: Translabyrinthine (if hearing non-serviceable) or retrosigmoid (if attempting hearing preservation, though unlikely at this size).
• Consent discussion: Facial nerve preservation (70-80% chance of good function at 1 year), hearing loss (likely complete), CSF leak (10-15%), meningitis, need for facial nerve rehabilitation if weakness occurs.
• Postoperative plan: ICU monitoring, early mobilization, facial nerve care, vestibular rehabilitation, follow-up MRI at 6 months.

MCQ/SBA Practice Questions

Question 1: A 45-year-old woman presents with progressive right-sided hearing loss. Asymmetric SNHL (≥15 dB at 2 frequencies). Most appropriate investigation?

Answer: MRI IAM with gadolinium. NICE guidelines recommend MRI for asymmetric SNHL to exclude VS (sensitivity ~100%). [30]

Question 2: 62-year-old with 1.2 cm Koos I VS, asymptomatic. Initial management?

Answer: Observation with MRI at 6 months, then annually. 40-60% of small VS show no growth over 5-10 years. [26,35]

Question 3: Bilateral VS on MRI. Genetic diagnosis?

Answer: NF2 (chromosome 22q12 mutation). Bilateral VS pathognomonic for NF2. [16,17]

Question 4: Critical artery to preserve during translabyrinthine VS resection?

Answer: AICA. Injury causes devastating cerebellar/brainstem infarction.

Question 5: Standard SRS dose to VS tumour margin?

Answer: 12-13 Gy (single fraction). Optimal tumour control with cranial nerve preservation. [49]

Question 6: Most specific MRI sign differentiating VS from meningioma?

Answer: IAM widening (> 90% specificity for VS). Meningiomas don't widen IAM.

Question 7: Best surgical approach for Koos I VS with serviceable hearing?

Answer: Middle cranial fossa approach (~80% hearing preservation for small intracanalicular tumours). [46,52]

Question 8: House-Brackmann Grade II facial nerve function?

Answer: Slight weakness on close inspection, complete eye closure, slight smile asymmetry. Good surgical outcome. [11]

Question 9: Emerging therapy for NF2-associated VS with progressive hearing loss?

Answer: Bevacizumab (anti-VEGF). 57% hearing improvement, 26% tumour shrinkage. [48]

Question 10: Red flag requiring urgent intervention in known VS?

Answer: Obstructive hydrocephalus (headache, vomiting, papilledema, CN VI palsy). Requires EVD/VP shunt.

---

14. Multidisciplinary Team (MDT) Management

Skull Base MDT Composition

Management of vestibular schwannoma requires specialized skull base expertise:

Core Members:

• Neurosurgeon (skull base fellowship trained)
• Otolaryngologist/ENT surgeon (neurotology/skull base)
• Neuroradiologist
• Radiation oncologist (stereotactic radiosurgery expertise)
• Audiologist
• Clinical nurse specialist

Extended Team:

• Neurologist (NF2 cases)
• Clinical geneticist (NF2, familial cases)
• Neuro-ophthalmologist (large tumours with visual involvement)
• Vestibular rehabilitation therapist
• Clinical psychologist (anxiety, adjustment to diagnosis)

MDT Discussion Points

For each patient, the MDT should systematically review:

1. Tumour Factors:

   • Size (Koos grade, maximum diameter)
   • Location (intracanalicular vs. CPA extension)
   • Growth rate (if serial imaging available)
   • Morphology (solid vs. cystic)
   • Relationship to critical structures (brainstem, AICA, CN VII)

2. Patient Factors:

   • Age and life expectancy
   • Comorbidities and anesthetic risk
   • Hearing status (PTA, SDS) - serviceable vs. non-serviceable
   • Facial nerve function (House-Brackmann grade)
   • Vestibular function and compensation
   • Occupational demands
   • Patient preferences and values

3. Treatment Options:

   • Observation: Surveillance protocol, growth thresholds for intervention
   • Radiosurgery: Dose, fractionation, expected outcomes
   • Surgery: Approach selection, extent of resection goals, functional preservation probabilities

4. Special Scenarios:

   • NF2: Bilateral disease, hearing preservation strategies, ABI candidacy
   • Only hearing ear: Conservative vs. hearing-preservation approach
   • Pregnancy: Defer intervention, growth monitoring
   • Previous treatment: Recurrent/residual disease management

Outcome Measures

Modern skull base programs track standardized outcomes:

Tumour Control:

• Gross total resection rate (GTR vs. NTR vs. STR)
• Radiosurgery control rate (stable/regressed vs. progression)
• Recurrence-free survival

Functional Outcomes:

• Hearing preservation (AAO-HNS class A/B serviceable hearing)
• Facial nerve function (House-Brackmann grade at 6 months, 1 year)
• Trigeminal function (corneal reflex, facial sensation)

Quality of Life:

• Penn Acoustic Neuroma Quality of Life (PANQOL) scale
• Tinnitus severity index
• Dizziness Handicap Inventory (DHI)
• Return to work rate

Complications:

• CSF leak rate
• Meningitis rate
• Vascular injury
• Mortality

---

15. Emerging Therapies and Future Directions

Molecular Targeted Therapy

Bevacizumab (Anti-VEGF):

• Humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF)
• Indication: Progressive NF2-associated VS with hearing loss
• Mechanism: Reduces tumour vascularity and vascular permeability; may restore blood-labyrinthine barrier
• Evidence: Plotkin et al. (2009) demonstrated 57% hearing improvement rate, 26% radiographic response in NF2 patients. [48]
• Dosing: 5-10 mg/kg IV every 2-3 weeks
• Limitations: Response not sustained after cessation; adverse effects (hypertension, proteinuria, thromboembolic events); high cost
• Current Role: Reserved for NF2 patients with progressive bilateral VS and deteriorating hearing; not approved for sporadic VS

Other Investigational Agents:

• mTOR inhibitors (Everolimus): Limited efficacy in early trials
• MEK inhibitors (Selumetinib): Under investigation for NF2
• FAK inhibitors: Preclinical data targeting focal adhesion kinase pathway
• HDAC inhibitors: Early-phase studies

Advanced Imaging Techniques

Diffusion Tensor Imaging (DTI):

• Maps white matter tracts including facial nerve course
• May improve preoperative surgical planning
• Identifies facial nerve location relative to tumour capsule [55]

High-Resolution 3D CISS/FIESTA Sequences:

• Exquisite anatomical detail of cranial nerves in cisterns
• Allows preoperative identification of facial nerve position
• Guides surgical approach selection

Functional MRI (fMRI):

• Limited role; may assess brainstem function in large tumours

Robotic Surgery

• Robotic-assisted microsurgery: Early feasibility studies; may enhance precision
• CyberKnife (robotic radiosurgery): Frameless, image-guided SRS; allows fractionation

Gene Therapy and Immunotherapy

• Oncolytic viruses: Preclinical studies; selective tumour cell lysis
• Immune checkpoint inhibitors: Limited rationale given benign histology
• Gene replacement therapy: Theoretical restoration of functional Merlin; far from clinical application

Hearing Rehabilitation Advances

Cochlear Implants for SSD:

• Traditional view: Cochlear implantation contraindicated in VS (nerve disruption)
• Emerging evidence: Selected patients with intact cochlear nerve may benefit from ipsilateral cochlear implantation post-treatment [56]

Auditory Brainstem Implants (ABI):

• Direct stimulation of cochlear nucleus in brainstem
• Implanted during VS surgery in NF2 patients
• Provides environmental awareness; speech understanding variable (10-30% open-set speech recognition)
• Outcomes improving with modern electrode arrays and processing strategies [47]

Bone Conduction Devices:

• Percutaneous BAHA (bone-anchored hearing aid): Osseointegrated titanium implant
• Transcutaneous bone conduction (Bonebridge, Sophono): Magnetic coupling; no skin penetration
• Effective for SSD; patient satisfaction high

Predictive Biomarkers

Research focus on identifying markers of growth and outcomes:

• MRI volumetric analysis: Automated tumour segmentation; growth rate quantification
• Radiomics: Extraction of quantitative imaging features; correlation with growth, cystic change
• Genomic profiling: Identification of mutations beyond NF2 (SMARCB1, ARID1A) that may predict growth or treatment response [23]
• Circulating biomarkers: Cell-free DNA, microRNA; early-phase studies

Quality of Life and Patient-Reported Outcomes

Shift toward patient-centered outcomes:

• PANQOL (Penn Acoustic Neuroma Quality of Life): Disease-specific validated instrument
• Facial Nerve Function: Not just House-Brackmann grade, but patient-reported facial function (FaCE scale)
• Shared Decision-Making Tools: Decision aids that present individualized risks/benefits of each treatment option based on patient-specific factors

---

16. Special Populations

Elderly (> 70), Pediatric, Pregnancy, Only Hearing Ear

Elderly: Slower growth; observation preferred unless symptomatic. SRS well-tolerated for growing tumours. Functional status trumps chronological age.

Pediatric: Rare; strongly associated with NF2 if present. Hearing preservation paramount for language development. Consider ABI for bilateral deafness.

Pregnancy: VS may grow faster (hormonal). Conservative management unless life-threatening. Defer elective treatment to postpartum.

Only Hearing Ear: High-stakes decision. Options: (1) Observation to maximize hearing duration, (2) SRS (70% hearing preservation), (3) Hearing-preservation surgery + ABI backup. Extensive counseling essential. [40]

---

17. Key Controversies

Observation vs. Early SRS for Small Tumours

40-60% never grow [26,35], favoring observation. Proactive SRS advocates cite 70% hearing preservation vs. 30-50% with delayed surgery. Current consensus: Individualized decision-making; both valid.

GTR vs. STR/NTR + Adjuvant SRS

GTR offers lower recurrence (2-5% vs. 10-20%) but risks facial nerve injury. Trend toward facial nerve preservation + planned SRS for residual (> 90% control). [57]

Single-Dose SRS vs. Fractionated RT

Limited comparative data. SRS remains standard; FSRT used selectively for larger tumours (2.5-3.5 cm). [58]

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and local guidelines. Always consult appropriate specialists and multidisciplinary teams for complex cases such as vestibular schwannoma.